Enochian Biosciences up after FDA accepts request to review potential hepatitis B cure

Lunai Bioworks

12/07/2021 12:59

** Shares of drug developer  ENOB.O  rise 7.2% to $5.64
premarket
    ** U.S. FDA accepts co's pre-Investigational New Drug
request to provide feedback for its potential cure for hepatitis
B virus (HBV) infection (https://refini.tv/3r2esK7)
    ** Pre-IND program allows companies the opportunity to
discuss the proposed project and receive guidance directly from
the FDA prior to submitting application to begin clinical trials
    ** Request was made based on promising data from a
proof-of-concept study conducted in mice - ENOB
    ** FDA's written comments are expected in fall this year
    ** As of last close, stock up 78.3% this year

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))